These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 20408946)

  • 1. Comparison between clevudine and entecavir treatment for antiviral-naïve patients with chronic hepatitis B.
    Kim HJ; Park DI; Park JH; Cho YK; Sohn CI; Jeon WK; Kim BI
    Liver Int; 2010 Jul; 30(6):834-40. PubMed ID: 20408946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment efficacy of clevudine, entecavir and lamivudine in treatment-naive patients with HBeAg-positive chronic hepatitis B].
    Bae SH; Baek YH; Lee SW; Han SY
    Korean J Gastroenterol; 2010 Dec; 56(6):365-72. PubMed ID: 21173560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy of entecavir switching therapy in chronic hepatitis B patients with clevudine-induced myopathy].
    Lee JW; Lee YJ; Lee JJ; Kim JH; Jung YK; Kwon OS; Choi DJ; Kim YS; Kim JH
    Korean J Gastroenterol; 2013 Jan; 61(1):30-6. PubMed ID: 23354347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of clevudine and entecavir for treatment-naive patients with chronic hepatitis B virus infection: two-year follow-up data.
    Yoon EL; Yim HJ; Lee HJ; Lee YS; Kim JH; Jung ES; Kim JH; Seo YS; Yeon JE; Lee HS; Um SH; Byun KS
    J Clin Gastroenterol; 2011; 45(10):893-9. PubMed ID: 21617542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression.
    Yoo BC; Kim JH; Kim TH; Koh KC; Um SH; Kim YS; Lee KS; Han BH; Chon CY; Han JY; Ryu SH; Kim HC; Byun KS; Hwang SG; Kim BI; Cho M; Yoo K; Lee HJ; Hwang JS; Kim YS; Lee YS; Choi SK; Lee YJ; Yang JM; Park JW; Lee MS; Kim DG; Chung YH; Cho SH; Choi JY; Kweon YO; Lee HY; Jeong SH; Yoo HW; Lee HS
    Hepatology; 2007 Oct; 46(4):1041-8. PubMed ID: 17647293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term treatment outcomes of clevudine in antiviral-naive patients with chronic hepatitis B.
    Kim SB; Song IH; Kim YM; Noh R; Kang HY; Lee HIe; Yang HY; Kim AN; Chae HB; Lee SH; Kim HS; Lee TH; Kang YW; Lee ES; Kim SH; Lee BS; Lee HY
    World J Gastroenterol; 2012 Dec; 18(47):6943-50. PubMed ID: 23322992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.
    Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI
    J Gastroenterol Hepatol; 2010 Aug; 25(8):1374-80. PubMed ID: 20659226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
    Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
    World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.
    Ono A; Suzuki F; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Suzuki Y; Saitou S; Arase Y; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Kumada H
    J Hepatol; 2012 Sep; 57(3):508-14. PubMed ID: 22659518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clevudine for chronic hepatitis B: antiviral response, predictors of response, and development of myopathy.
    Jang JH; Kim JW; Jeong SH; Myung HJ; Kim HS; Park YS; Lee SH; Hwang JH; Kim N; Lee DH
    J Viral Hepat; 2011 Feb; 18(2):84-90. PubMed ID: 20196804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan.
    Suzuki F; Hosaka T; Suzuki Y; Sezaki H; Akuta N; Fujiyama S; Kawamura Y; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Suzuki Y; Kumada H
    J Gastroenterol; 2019 Feb; 54(2):182-193. PubMed ID: 30136216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
    Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C
    Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Long-term clevudine therapy in nucleos(t)ide-naïve and lamivudine-experienced patients with hepatitis B virus-related chronic liver diseases].
    Lee HJ; Eun JR; Lee CH; Hwang JS; Suh JI; Kim BS; Jang BK
    Korean J Hepatol; 2009 Jun; 15(2):179-92. PubMed ID: 19581770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety.
    Yuen MF; Seto WK; Fung J; Wong DK; Yuen JC; Lai CL
    Am J Gastroenterol; 2011 Jul; 106(7):1264-71. PubMed ID: 21364549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients.
    Suzuki F; Toyoda J; Katano Y; Sata M; Moriyama M; Imazeki F; Kage M; Seriu T; Omata M; Kumada H
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1320-6. PubMed ID: 18554238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of Clevudine-Resistant Chronic Hepatitis B: A Multicenter Cohort Study.
    Cho EY; Yim HJ; Jung YK; Suh SJ; Seo YS; Kim JH; Kim HS; Lee SH; Ahn SH; Lee JI; Jeong SH; Kim JW; Lee JW; Kim IH; Kim HS; Park SJ; Lee JM; Hwang SG;
    Gut Liver; 2017 Jan; 11(1):129-135. PubMed ID: 27538443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of lamivudine-resistance mutations on entecavir treatment outcome in hepatitis B.
    Koffi J; Egounlety R; Pradat P; Lebosse F; Si-Ahmed SN; Lussier V; Chevallier P; Bailly F; Zoulim F
    Eur J Gastroenterol Hepatol; 2014 Feb; 26(2):146-54. PubMed ID: 24025974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of 48-week clevudine therapy for chronic hepatitis B].
    Kim MH; Kim KA; Lee JS; Lee HW; Kim HJ; Yun SG; Kim NH; Bae WK; Moon YS
    Korean J Hepatol; 2009 Sep; 15(3):331-7. PubMed ID: 19783882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B.
    Marcellin P; Mommeja-Marin H; Sacks SL; Lau GK; Sereni D; Bronowicki JP; Conway B; Trepo C; Blum MR; Yoo BC; Mondou E; Sorbel J; Snow A; Rousseau F; Lee HS
    Hepatology; 2004 Jul; 40(1):140-8. PubMed ID: 15239097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
    Zheng MH; Shi KQ; Dai ZJ; Ye C; Chen YP
    Clin Ther; 2010 Apr; 32(4):649-58. PubMed ID: 20435234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.